跳至主要内容
临床试验/CTRI/2025/10/096351
CTRI/2025/10/096351尚未招募不适用

ASSESSMENT OF DISEASE STATUS, ADVERSE EVENTS AND QUALITY OF LIFE DUE TO POLYPHARMACY AMONG CHRONIC KIDNEY DISEASE PATIENTS: A PROSPECTIVE STUDY.

KLE College of Pharmacy Belagavi1 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2025年10月28日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
136
试验地点
1
主要终点
•To Evaluate the effect of Polypharmacy on disease status in Patients with Chronic Kidney Disease.

研究概览

简要总结

This prospective study aims to evaluate the impact of polypharmacy on disease status, adverse events, and quality of life among patients with chronic kidney disease (CKD). Patients with CKD stages 1–5, including those on dialysis, who are taking five or more medications will be enrolled. The primary objective is to assess the effect of polypharmacy on disease status. Secondary objectives include identifying and reporting adverse drug events and evaluating quality of life using the Medication-Related Quality of Life (MRQoL) questionnaire. Adults aged 18 years and above who provide informed consent will be included, while patients with cognitive impairment or unwilling to give consent will be excluded.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • 1.Patients diagnosed with chronic kidney disease Stages 1-5 or those receiving dialysis.
  • 2.Patients Taking five or more medications concurrently.
  • 3.Adults aged 18 years or older.
  • 4.Patients Who Provide Informed Consent to Participate in the study.
  • 5.Referred Patients are included.

排除标准

  • 1.Patients with Cognitive impairment that prevents from completing surveys or providing Informed Consent.
  • 2.Patients who are not willing to provide consent.

结局指标

主要结局

•To Evaluate the effect of Polypharmacy on disease status in Patients with Chronic Kidney Disease.

时间窗: One-time assessment at the time of enrollment.

次要结局

  • •To assess and evaluate the effect of Polypharmacy on Quality of Life in Chronic Kidney Disease Patients using Medication Related Quality of Life (MRQOL).(One-time assessment at the time of enrollment.)
  • •To assess and report the adverse events in Patients with Chronic Kidney Disease.(One-time assessment at the time of enrollment.)

研究者

发起方
KLE College of Pharmacy Belagavi
申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Darshan Belagali

kLE College of Pharmacy Belagavi

研究点 (1)

Loading locations...

相似试验